AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26095784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 26095784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 565
Study 24169342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (two nursing counselling sessions and two instructive sessions with a physical therapist)
Number of subjects: 161
Study 24169342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 161
Study 24169342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study 21975231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous transplant of bone marrow-derived stem cells
Number of subjects: 8
Study 21975231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stem cell treatment)
Number of subjects: 8
Study 19187518 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 0
Study 19187518 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 0
Study 16899031 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 93
Study 16899031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 16899031 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) or Placebo
Number of subjects: 93
Study 15205853 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 mM sodium nitroprusside (SNP) solution (2.16 mg/ml)
Number of subjects: 31
Study 15205853 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 31
Study 11348560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-antioxidant diet (5-7 servings of fruit and vegetables per day) for 2 weeks
Number of subjects: 25
Study 11348560 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray-dried antioxidant supplement (30 g) for 2 weeks
Number of subjects: 25
Study 11348560 — intervention group
Group type: COMPARATOR
Intervention: Control (2-week depletion period with low-antioxidant diet)
Number of subjects: 25
Study 9421873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian solution using BUGS implementation of Gibbs sampling
Number of subjects: 0
Study 9421873 — intervention group
Group type: COMPARATOR
Intervention: Naive analyses using observed risk of events in control groups
Number of subjects: 0
Study 9421873 — intervention group
Group type: COMPARATOR
Intervention: Naive analyses using average risk in control and treatment groups
Number of subjects: 0
Study 7956627 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-crystal contact thermography (LCT) assessing mean plantar foot temperature (MFT)
Number of subjects: 50
Study 7956627 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with PVD)
Number of subjects: 50
Study 3540836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (25 IU of dl‐alpha‐tocopherol)
Number of subjects: 178
Study 3540836 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar volume of drug vehicle)
Number of subjects: 178
Study 29019274 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and balance program combined with whole-body vibration
Number of subjects: 73
Study 29019274 — intervention group
Group type: COMPARATOR
Intervention: Strength and balance program without whole-body vibration
Number of subjects: 73
Study 27523436 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of resveratrol/day for 4 weeks
Number of subjects: 20
Study 27523436 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study 24231167 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 206
Study 23446067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild lumbar decompression
Number of subjects: 45
Study 20562078 — intervention group
Group type: EXPERIMENTAL
Intervention: PercuSurge GuardWire system (protection group)
Number of subjects: 118
Study 20562078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 118
Study 19472804 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 75
Study 19472804 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 75
Study 19472804 — intervention group
Group type: COMPARATOR
Intervention: No preoperative analgesia (Control)
Number of subjects: 75
Study 15899689 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms about safe work practices
Number of subjects: 2541
Study 15899689 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms about smoking
Number of subjects: 2541
Study 15899689 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms about healthy eating
Number of subjects: 2541
Study 12840088 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 540
Study 12840088 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation
Number of subjects: 540
Study 12840088 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus high-dose chemotherapy and stem-cell transplantation
Number of subjects: 540
Study 10821295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg
Number of subjects: 369
Study 10821295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 369
Study 10821295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 12 mg
Number of subjects: 369
Study 10821295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 8690280 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 34
Study 8690280 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.6 mg/24 hr)
Number of subjects: 34
Study 2002136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 59
Study 2002136 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 59
Study 2002136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6407042 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cyano-imipramine
Number of subjects: 0
Study 31230825 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 360
Study 31230825 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 30418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practices for improving social communication impairment
Number of subjects: 0
Study 30418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular and targeted interventions
Number of subjects: 0
Study 30418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive treatment designs and Sequential Multiple Assignment Randomized Trial
Number of subjects: 0
Study 27054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-up (FCU) intervention
Number of subjects: 998
Study 27054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in FCU services
Number of subjects: 998
Study 27054823 — intervention group
Group type: COMPARATOR
Intervention: Nonengagers in FCU services
Number of subjects: 998
Study 27054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagers in FCU services
Number of subjects: 998
Study 25174948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with CPP‐ACP (GI)
Number of subjects: 72
Study 25174948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP‐ACP (GII)
Number of subjects: 72
Study 25174948 — intervention group
Group type: COMPARATOR
Intervention: Control group without gum (GIII)
Number of subjects: 72
Study 22892742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 25
Study 22892742 — intervention group
Group type: EXPERIMENTAL
Intervention: Largal Ultra
Number of subjects: 25
Study 22892742 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetraacetic acid
Number of subjects: 25
Study 22892742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubuliclean
Number of subjects: 25
Study 19237984 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with Macintosh laryngoscope
Number of subjects: 60
Study 19237984 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with Glidescope
Number of subjects: 60
Study 19237984 — intervention group
Group type: COMPARATOR
Intervention: Total intubation scores
Number of subjects: 60
Study 19237984 — intervention group
Group type: COMPARATOR
Intervention: Muscle rigidity
Number of subjects: 60
Study 19237984 — intervention group
Group type: COMPARATOR
Intervention: Arterial pressures or heart rate
Number of subjects: 60
Study 17890465 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular waveform HFCWO
Number of subjects: 15
Study 17890465 — intervention group
Group type: COMPARATOR
Intervention: Sine waveform HFCWO
Number of subjects: 15
Study 15020170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (received reminder-feedback and educational outreach intervention)
Number of subjects: 2992
Study 15020170 — intervention group
Group type: COMPARATOR
Intervention: Control Group (received only the screening program)
Number of subjects: 2992
Study 11817531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted venous drainage (VAVD)
Number of subjects: 72
Study 11817531 — intervention group
Group type: COMPARATOR
Intervention: Gravitational drainage (GD)
Number of subjects: 72
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tooth extraction (group II)
Number of subjects: 207
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tooth extraction (group III)
Number of subjects: 207
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoperiosteal flap elevation (group IV)
Number of subjects: 207
Study 9524970 — intervention group
Group type: COMPARATOR
Intervention: Baseline (group I)
Number of subjects: 207
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Broth culture technique
Number of subjects: 207
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric Isolator technique
Number of subjects: 207
Study 9524970 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic susceptibility
Number of subjects: 207
Study 7640538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 741
Study 7640538 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 741
Study 2696671 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative subconjunctival 5-fluorouracil (5-FU) injections
Number of subjects: 196
Study 2696671 — intervention group
Group type: COMPARATOR
Intervention: No postoperative 5-fluorouracil (control group)
Number of subjects: 196
Study 2696671 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraocular pressure (IOP) control
Number of subjects: 196
Study 21837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-containing antacid
Number of subjects: 0
Study 21837 — intervention group
Group type: COMPARATOR
Intervention: Ca-free antacid
Number of subjects: 0
Study 31896620 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg
Number of subjects: 53
Study 31896620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31623400 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg/day)
Number of subjects: 30
Study 31623400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28748995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8 weekly 45-minute sessions)
Number of subjects: 88
Study 28748995 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 26010368 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 46
Study 23758961 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that received an extension
Number of subjects: 73
Study 23758961 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with 80% power
Number of subjects: 73
Study 23758961 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 73
Study 21830080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle subtraction osteotomy
Number of subjects: 154
Study 21830080 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic patients)
Number of subjects: 154
Study 19575270 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with uncontrolled BP
Number of subjects: 226
Study 19575270 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with controlled BP
Number of subjects: 226
Study 19575270 — intervention group
Group type: COMPARATOR
Intervention: Whites with uncontrolled BP
Number of subjects: 226
Study 19575270 — intervention group
Group type: COMPARATOR
Intervention: Whites with controlled BP
Number of subjects: 226
Study 17254697 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O plus IS
Number of subjects: 96
Study 17254697 — intervention group
Group type: COMPARATOR
Intervention: TVT-O alone
Number of subjects: 96
Study 15126747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) using radiofrequency (RF) technique
Number of subjects: 150
Study 15126747 — intervention group
Group type: COMPARATOR
Intervention: Traditional tonsillectomy (TE)
Number of subjects: 150
Study 11677476 — intervention group
Group type: EXPERIMENTAL
Intervention: Multibite forceps
Number of subjects: 250
Study 11677476 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps
Number of subjects: 250
Study 10216644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 50
Study 8161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial shunt (8‐mm diameter portacaval H grafts with collateral ablation, n = 14)
Number of subjects: 30
Study 8161260 — intervention group
Group type: COMPARATOR
Intervention: Total shunt (16‐mm diameter grafts, n = 16)
Number of subjects: 30
Study 8161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial shunt
Number of subjects: 30
Study 8161260 — intervention group
Group type: COMPARATOR
Intervention: Total shunt
Number of subjects: 30
Study 3415549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (46% to 98% scattering)
Number of subjects: 5
Study 3415549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (75% contrast target)
Number of subjects: 5
Study 3415549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (5% contrast target)
Number of subjects: 5
Study 3415549 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity measurements with projected high-contrast targets
Number of subjects: 5
Study 31000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 2.5 mg dexamethasone
Number of subjects: 42
Study 31000508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone injection)
Number of subjects: 42
Study 30948284 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed testing (PlGF measurement revealed to clinicians)
Number of subjects: 1023
Study 30948284 — intervention group
Group type: COMPARATOR
Intervention: Concealed testing (PlGF measurement concealed from clinicians)
Number of subjects: 1023
Study 30948284 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed testing
Number of subjects: 1023
Study 30948284 — intervention group
Group type: COMPARATOR
Intervention: Concealed testing
Number of subjects: 1023
Study 26911532 — intervention group
Group type: EXPERIMENTAL
Intervention: Family member-based supervision package
Number of subjects: 554
Study 26911532 — intervention group
Group type: COMPARATOR
Intervention: Usual service
Number of subjects: 554
Study 25590358 — intervention group
Group type: EXPERIMENTAL
Intervention: Griffonia simplicifolia/magnesium complex (50 and 200 mg, respectively), orally administered twice a day for 3 months
Number of subjects: 0
Study 25590358 — intervention group
Group type: COMPARATOR
Intervention: No therapy for MS
Number of subjects: 0
Study 23442276 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization training group (TG, n = 16)
Number of subjects: 28
Study 23442276 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 28
Study 23442276 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 22029641 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐acting MPH (0.5 mg/kg)
Number of subjects: 12
Study 22029641 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 17914251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 88
Study 17914251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 16981274 — intervention group
Group type: EXPERIMENTAL
Intervention: Weiansan (WAS) 5 g, 3 times a day
Number of subjects: 76
Study 16981274 — intervention group
Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC) 4 tablets, 3 times a day
Number of subjects: 76
Study 16981274 — intervention group
Group type: COMPARATOR
Intervention: Model group (ranitidine + MNNG)
Number of subjects: 76
Study 16981274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose WAS
Number of subjects: 76
Study 16981274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose WAS
Number of subjects: 76
Study 16981274 — intervention group
Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC)
Number of subjects: 76
Study 12604410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 0
Study 12604410 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 11083243 — intervention group
Group type: EXPERIMENTAL
Intervention: CARTO-guided radiofrequency catheter ablation
Number of subjects: 80
Study 11083243 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency catheter ablation
Number of subjects: 80
Study 11083243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CARTO-guided and conventional approaches
Number of subjects: 80
Study 8680703 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bronchoalveolar lavage (BAL)
Number of subjects: 58
Study 8680703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up bronchoalveolar lavage (BAL) after 4 days
Number of subjects: 58
Study 8680703 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IL-8 concentrations in BAL fluid
Number of subjects: 58
Study 8680703 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up IL-8 concentrations in BAL fluid after 4 days
Number of subjects: 58
Study 1404043 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate
Number of subjects: 34
Study 1404043 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 34
Study 3924425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mile continuous exercise
Number of subjects: 36
Study 3924425 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 minute interval (1:1, work:rest)
Number of subjects: 36
Study 3924425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minute interval (1:1-1/2, work:rest)
Number of subjects: 36
Study 3924425 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 31977602 — intervention group
Group type: EXPERIMENTAL
Intervention: synthDIR
Number of subjects: 100
Study 31977602 — intervention group
Group type: COMPARATOR
Intervention: FLAIR
Number of subjects: 100
Study 31977602 — intervention group
Group type: COMPARATOR
Intervention: trueDIR
Number of subjects: 100
Study 29802293 — intervention group
Group type: EXPERIMENTAL
Intervention: eLearning
Number of subjects: 245
Study 29802293 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 245
Study 27503640 — intervention group
Group type: COMPARATOR
Intervention: EDP-239 (100 mg single dose)
Number of subjects: 0
Study 25436815 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplementation (B complex, C, and E)
Number of subjects: 0
Study 25436815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 25436815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23108516 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 160
Study 23108516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g orally
Number of subjects: 160
Study 23108516 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg orally
Number of subjects: 160
Study 23108516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 19850639 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC detection before chemotherapy
Number of subjects: 115
Study 19850639 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC detection after chemotherapy
Number of subjects: 115
Study 19850639 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC detection before neoadjuvant chemotherapy
Number of subjects: 115
Study 18042474 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS)
Number of subjects: 267
Study 18042474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 16136771 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 14
Study 16136771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 14
Study 16136771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 471
Study 12898832 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 471
Study 10599797 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-DL-threo-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 10
Study 10599797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8557011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg‐1, total dose of 0.5 mg kg‐1)
Number of subjects: 56
Study 8557011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine administration
Number of subjects: 56